Menu
GeneBe

FAAH2

fatty acid amide hydrolase 2

Basic information

Region (hg38): X:57286705-57489193

Previous symbols: [ "AMDD" ]

Links

ENSG00000165591NCBI:158584OMIM:300654HGNC:26440Uniprot:Q6GMR7AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FAAH2 gene.

  • Inborn genetic diseases (25 variants)
  • not provided (15 variants)
  • not specified (3 variants)
  • FAAH2-related condition (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FAAH2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
2
clinvar
3
missense
29
clinvar
5
clinvar
1
clinvar
35
nonsense
1
clinvar
1
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
1
1
2
non coding
1
clinvar
1
Total 1 0 30 6 4

Variants in FAAH2

This is a list of pathogenic ClinVar variants found in the FAAH2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-57286924-T-C FAAH2-related disorder Benign (Apr 14, 2020)3056042
X-57286949-C-T Benign (Sep 25, 2017)771788
X-57286952-C-T FAAH2-related disorder Uncertain significance (Jan 30, 2024)3033341
X-57286970-C-T not specified Uncertain significance (Aug 08, 2022)2305676
X-57286983-G-T not specified Uncertain significance (Jun 01, 2023)2519124
X-57292520-A-C Likely benign (Feb 01, 2023)2660714
X-57292545-C-T Likely benign (Feb 28, 2018)547083
X-57292558-A-G not specified Uncertain significance (Oct 03, 2022)2315055
X-57292569-TGTCAAGTACAG-T Pathogenic (Dec 03, 2017)522688
X-57292583-G-A Likely benign (-)1205882
X-57331619-T-A not specified Uncertain significance (May 17, 2023)2547016
X-57331621-A-G not specified Uncertain significance (Jan 29, 2024)3091512
X-57331624-A-C not specified Uncertain significance (Apr 05, 2023)2525096
X-57331630-C-T Likely benign (Nov 01, 2022)2660715
X-57331631-G-A not specified Uncertain significance (Dec 27, 2023)3091513
X-57331666-G-A not specified Uncertain significance (Jul 14, 2021)2412025
X-57331677-G-A FAAH2-related disorder Likely benign (Feb 27, 2019)3039659
X-57331751-T-C not specified Uncertain significance (Jan 19, 2022)2209839
X-57331760-G-A not specified Conflicting classifications of pathogenicity (Oct 26, 2021)252796
X-57331770-C-T FAAH2-related disorder Likely benign (Jan 22, 2020)3051223
X-57331774-T-C Uncertain significance (May 01, 2022)2660716
X-57339912-GTTCTCTAGAGGGACAGAACTAATAGGATAGATTTATACATGAAGGGGAGTTTATTAAAGAGTATTGGCTCACAGGATAACAAGTTGAAGTCCCACAATAGGCCGTCTGCAAGCTGAGGAGCAAGGAAGCCAGTCTGTGTCCCAAAACCTCAAAAGTAGGAAAGCTGACAATGCAGCCTTTAATCTGTGGCCAAAGGCCCAAGAGCCCCCGGCAAACCACTTGTGTGAGTCCGAGCGTCCAAAAGCTGAAGAACTTGGGGTCCGATGTTTGAGGACAGGAAGCATGCAGCATGGAGGAAAGATGAATGCTGGAAGACACAGCAACTCTGCTCTTTCCAATTTCTATCTGCTTTATTCTAGCCACGCTGATTAGATGGTGCCTGTTGTGACTGGGGATGGGCCTGCCTCTCCCAGTCCACTGACTCGAATATTAATCTCCTTTGCAACACTCTCACAGACACACCCAGGAAGAATACTTTGCATTTTTTGATTCAATCAAGTTGACGCTCAGTATTAACCATCAAACTGGGTATATACCCAAAGGAATATAAAGCATTTTATTATAAAGATACATGCACACATATGTTCATTGTAGCACTATTCACAATAGCAAAGACATGGAATCAACCCAAATGCCCATCAATGATAGATTGAATAAATAAAATGTGGTACAAATACAACACGGAATGCTATTCAGCCATGAAAAGGAACAAGATCATGTCCTTTGCAGGGACATGGATGGAGCTGGAAGCCATTATTCTCAGTAAACGAATGCAGGGATAGAAAAGCAAACACAGCATGTTCTCACTTATAAGTGGGATGGGAGCTGAATGATTAGAACACATAGACACATGGTGGGGAACAACACACACTTGGGCCTGTTGGGGGATGTTGGGAGAAAGGAGAGCATCAAGAAGAATAGCTAATGGCTGCTGGGCTTAATACCTAGGTGATGTGTTGATCTGTGCTGCCAACCACCATGGCACGCATATACCTGTGTAGCAAACCTGCACATCCTGCACATGAACCCCAGAACTTAAAAGTTGATGGAAAAAAAAAAATAAGAACTCTTTTCTATATGAGAGAATTAAGAAAAAGCAGACACACAAACACAGACCCGGGGAAGAAATATCCTCAGGGAAAACCTTATCAGTAATTACTTTAAAATGTAAATGGCTTAATATTCTCAAGTAATATAGATGAATAGAATAAAATTATGATCTAAATATATGCTGTGAACAAAAGACTCACTTTGGATCTAAAGACACAAAAAGGTTGAAAGTGAAAAGATGGAAAAAGATATTCCATGCAAATAGTATATTAGATTATTTATTTGCAAGTATTTTGTGTTTCTTGTAGGTGGTGAGGGCTGCACACTGGCAGCTGCCTGCTCAGTTATTGGTGTGGGCTCTGATATTGGTGGTAGCATTCGAATGCCTGCTTTCTTCAATGGTATATTTGGACACAAGCCTTCTCCAGGTAATGTTAATATGATCAGAAGGGTGGTTCTACTTTTATAATTCAGAGCAATTCAGAAATTTTGTTCTAGCAGGATTATCTTGCTTATCAGGGTGATTATTATATATTTCTCAATGTTCTTAAATAAAACTAGCTACTGTTTATTGAGCACCAACTCTGGGATTGGTGCACAAAATTGTGCAAGGCTTTCCTATAACTAATGTCTTTCAATAGTTATAATAGTTGTTTTTTTTTTTTTCAGAAAGTTATCCCCAATTTACAAATGACAAATTCAAAGCTCAGAAAGATTAAATAAACCGGCTCCAAATTAAATAGTTAAACAAGTAAATCATAGTGCTAGGATTCAAACCTACTTGGATTACAGGAGGCTGTTTTCTATCCACTGTACTAAAATGACTTATCAGTTAAATTTGATTTTCCCTCATTTAAAGGGTAAAATAACACAGTTTCAGAAACAGTGGAAAGAAAAATTCTGTCACCTAGAAACTCCAGTTATTGGCATTTACTGTTTTTTCAATGAATTCAAGGAGTATTTATTTTGTATTATTTATGGTGGTAAGAATGTCAAAGCAGACTCCCTGCATTCAAGGAACTTAAAATCTTCTAGGCTTTCAAAAAGTGATTTAAAGGTAATATAAGGTAGTCTAATAAATATAATTGTGGTATAGTAAAGCAGAATATTTTGAACTTTAGATTAATCATAAAAATATGCTAAGAATAAATCCTCATTTGATCATGGTTTTTAGGAATCAGTACTATAACAATGGTCCGTATACACCATGGAATGCTATGTAGCCATGAAAAAGAACAAGATCATTTCCTTTGCAGGGACATAGATGGAACTGGAGGCCATTATCCTTAGCAAACTAACGCAGGAACAGAAAACCAAATGTGACATATTTTCACTCATAAGTGGGAGCTAAATGTTGAGAACATGTGAGCACATAGAGGGGAACAACAAACACTGGGGACCTTTCAGAGGGCAGAGGGTGGGAGGATGGTTAGGATCAGGAAAAATAAATAATGGGTACTAGTCTTAATACCTGGATGATGAAATAGTCTGTAGAACAAACCCCCATGACACGTTTACCTATGTAACAAACCTGCACATGTACCCCTAAACTTAAAAGTTAAAAAGAAAGATAAATCCTAGCTCTTCATGACTTTAAAGAATTACGCACAAAAAGAGTACTGAAAATTGGCCTGCTAGGAGTTGACCTATTTTTTTTCCCTTCCATATTTTATTCTACGTTCAGGGGGCACATATGCGGGCTTATTACATGGGTAAATTGTGTGTCCATGTGGTTTGGTGTACAAATGATTTCATCATTCACGTAGTGAACACAGTCCCTGATAGGTAGTTTTTTGATCCTTGCCCTCCTCCCATCCTCCACCTTTAAGTAGGCTCTGGTTTCTCTTGTTTTCTTCTTTCTGTCCATGTGTACTCAAGGTTTAGTTCCACATACAAGTGAGAAGATGTGGTAGTTTCTTTTCTGTTCCTGTGTTAATTAGCTTAGGATAATAATGGCCTCTAGCTGCATCCATACTATTGCAAAGGAATATTTTATTCCTTTTTATGGCTGCATAGTATTTCATGGTGTAAAGGTACTACATATTCTTTATTCAGTCCACTGTTGATGGGAAGCTGGATTGATTCCATGTCTCTGCTATTCTGAATACTGCTGTGATAAACATATGAGTTCATTTGTCTTTTTGGTAGAACAAATAATTTTCCTTGGAGTATATATCTGGTAATGGGATCACTGGGTTAAATGGCAGTTCTAAGTTATTTGAGATATCTCCAAACTCCTTTCCAAAGGGCTGAACTAATTTACATTCTTACCAACAGTATATAAGCATTCTCTTTTCTCTGCAGCCTCATCAGTGTCAGTTATTTTTGGATTTTTTCAATGATTGCCATTCTGACTTGTGTGAGACAGTATCTCATTGTGGTCTTTATATGCATTTCTCTGATGATTAGTGATGTTGATCATTTTTTATAGGTTTCTTGGCTGCTTGTACATCTTCTTTTGAGAAGTGTCCATTCATGTCATTTTCTCACTCTTTAATTGATTATTTACTTTTTGCTTGTTGATTTCTTTAAGTGCCTTATAGATTCTGGATATTAGACTTATGTTGGATGCATGGTTTCTGAATATTTTCTCCCATTCTGTAGACTGTATGTTTACTCTTTTGATAATTTCTTTCGCTATGCTGTAGCTCTTTAGCTTAATTTGGTCCCACTTGCCAAATTTTCTTTGAAATTGCTTTTGGAGACTTAGCCATAAATTATTTGCTAGTCCAGTGTTGAGAAGGGTATCTCCTAGGCTTTCCTCTAGCATTTTTATAGGTTGGGATCTTACATTTAAATATTTAATTTATATTTAGTTAATTTTTGCATATGGTGAAAGGTAGGGATCCAGTTATATTTTTCTGCATATGGCTGGCCAGTTATCCCGGCGCCATTTATTGAATAGGAAGTCCTGTTACCCTTGCTTTTGTAAATTTTGTCTAAGATCAGATCGTTGTAGGTTTGCAGCTTTATTTCTGGGATCTCCATTCTGTTCCATTGGTCTATATATCTGTTTTTATACCAGCTTCATGTGGTTTTGGTTACATTAGTCGTACAATACAGTTTTAAGTTGGGTAAAGTGATTTATTTGCCTTTTGTTTCCTTAGGATCCCTTTGGCTGTTCAGATGTATTATTGGTTCCATATGAGTTTTAGAATAGCTTTTTTTTTTTTTAAATTCTGTGAAAAATAACAGTATTTCGATAGGGATAACATTGAATATGTAAATTACTTTGGAAAGTATGGCAATTTTAATGATATTGATTCTTCCAATCCATGATAATGGAATATTTTTCTGTTTGTTTCATCTCATATTTTTTCAGCAGTATTTTGTTGTTCTTTTTGTAAAGATGTTTCACCTCTTTGGTTAGTGGTATTTCTAGATATTGTAGTTTTGGTGTGGCTATTGTAAATGGGATTGCATTTTTTATTTGGCTTACCAAGAATATTATTGAAGTGTAGAAATGCTACTGATTTCTGTACATGAATTTTGTGTCCTGAAACTTTACTAAAGTCATTTATCAATTCCAGGAGCCTTTTGGGAGAGTCTTTTTGAATCATATTGTCAGCAGAGAGAGATTGACTTTGTCTTTGTCCTATTTGAATGCCCTTTATTTCTTTCTCATGCCTAAATGCTCTGGCTAGGGCTTCCAGTATTATGTTGAATAGGAGTGGTGAGACTGGACACCTTTGTCTTACTGCAGGTCTCAAGGGGAATTATTCTGTCTTTTGCCCATTCAATATGATGTTGGCTGTGGGTTTGTCATAATTAGCTCTTATTATTTTGATGTATGCTCTTTTGATGACTATTCTTCTAAGGTTTTTATCATGAAGGAATGTTTGATTTTATTGAAGTCTCTTTCTGAATCTATTGAGATGATTATATCTTTTTTTGTTTTAAATTCTGTGTATGTGGTAAATCACTTTTTTTTATTTGCTTATGTTGAATTAACATTGCATCCCAGGAGTAAAGCTTACTCAACTGTTGTGAATTAACATTTTGATGTGCTGCTGAAATAAGTTTGCTAGTATTTTGTTGAAATTTTTTCTGTCTGTATTCATCAGGGATATAGTCATGACTTTTGTTGTTGTGTCTGTGCCAGATTTTGGCATCAGGATGCTTGATTTCTAGAATGAGTTAAAGAGCATCCTCTCCTCAATTTTTTTTTTTTTTTGGAATAGTTTCAGTAGTATTGGTACCAGGTTTTCTCCCTTCCCTTCCCTTCCCTCCTCTCCCCTCCCCTTCCCTTCCCTTTCTTTTTGCATTCCTGGTAGACTTCAGCTGTGAATCCATCTGGTCGATGTCTTTTGTGCATTGGTAGGTTTTTTTTAATTACTGAATTAATTTCGAAGCTTGTTATTTGTCTTTTCAAGATTTCTCTTTCTTCCTGGTTCAATCTTCAGAGGTTGTGTGTTTTCAGAAATGTATCCATTTTTTCTAGATTTTCTAATTTGTGTCCATAGAGGTGTTCATAAAAACCACTGAGGATCTTTTGTATTTCTGTAGGATCAGTTGTAACTTCACCTTTGTCATTTCTGATTGCATTTATTTGGACTTTTTTTTTCTTTGTTAATCTAGCCAGCAGTCTATCTTGTTTATTCCTTCAAAAAAGAGACTCTTGGTTAAATTGATCTTTTGTATGAACTTTTGCATGTCAATTTCATTGGTTCTACCCAATTATAGTTACATATTTTCTACTGCAAGCTTTGAGTTTGGATTGCAATTTATTTTCTAGTTCCTTTGGGTGTGATTAGATCACTGATTTTAGATCTTTCTAACTTTTTGATTCAGGCTTTTAACATCTTAAACTTTACTCTTAACAGTGCATTACCTGAATCACAAAGATTTTGGTAAGTTATTTTTTATTTTCATTAACTTATAATAATCTTTTGATATATACCTTAATTTCATCGTTCACCCAAAAGTTATTCAGGAAAAAGTTATTTAATTTGCATGTATTTGTGAATTTTTGAAATATTTTATTTATATTGGTTTCTATACTTTTTGCACTCTGATCCAAGAGTGTGTTTGGTATGATTTAAATTTTTTTGAATTTATTGAGACTTGCTGTATGACCAAACTTGTGGTCAATCTTAGAATACATTCCTTGTGCAGATGAGAGAAATATATATTCCATGATTGTTGGGTGGACTATTTTGCAGATGTCTATCAGGTGCAATTAGTCAAATGTTAAGGTTATATCCTTCATTTATTGGTTAGTTTTCTGCCTCAAAGATCTGTCTAAGGCTGTCAGTGGGGTTTTGAAATCTCCCACTATTATTGTGTGGCTAAGTTTTTTCTTAGGTCAAAAAGAACTTGTTTTATGAATTTGAGTGCTCCAAATTGGGTGCATGTATATATAA-G Intellectual disability;Autistic behavior Uncertain significance (Jan 09, 2020)977452
X-57341301-G-A not specified Uncertain significance (Oct 12, 2022)2317969
X-57341358-T-C not specified Uncertain significance (Aug 02, 2023)2592286
X-57341373-G-C not specified Uncertain significance (May 25, 2022)2407435

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FAAH2protein_codingprotein_codingENST00000374900 11202491
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.89e-210.00003071253931182321257430.00139
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-3.633251861.750.00001293428
Missense in Polyphen9360.0351.54911027
Synonymous-4.6611566.61.730.000004451054
Loss of Function-2.202616.41.590.00000117319

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.003790.00357
Ashkenazi Jewish0.000.00
East Asian0.001870.00136
Finnish0.00006350.0000462
European (Non-Finnish)0.002670.00191
Middle Eastern0.001870.00136
South Asian0.0007460.000425
Other0.001370.000978

dbNSFP

Source: dbNSFP

Function
FUNCTION: Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes monounsaturated substrate anandamide preferentially as compared to polyunsaturated substrates. {ECO:0000269|PubMed:17015445}.;
Pathway
Metabolism of lipids;anandamide degradation;Arachidonic acid metabolism;Metabolism;Fatty acid metabolism (Consensus)

Recessive Scores

pRec
0.110

Intolerance Scores

loftool
0.922
rvis_EVS
-0.29
rvis_percentile_EVS
33.42

Haploinsufficiency Scores

pHI
0.171
hipred
N
hipred_score
0.187
ghis
0.495

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.180

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Gene ontology

Biological process
arachidonic acid metabolic process
Cellular component
lipid droplet;integral component of membrane
Molecular function
fatty acid amide hydrolase activity;oleamide hydrolase activity;anandamide amidohydrolase activity